Opportunity
Federal Register #2026-23413
FDA drug-approval notices and IHS Fiscal Year 2027 CHEF threshold
Buyer
U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)
Posted
November 18, 2026
Respond By
December 18, 2026
Identifier
2026-23413
This notice combines FDA drug-approval actions with an Indian Health Service CHEF threshold announcement. - Agencies: U.S. Department of Health and Human Services (HHS), including the Food and Drug Administration (FDA) and its Center for Drug Evaluation and Research (CDER); Indian Health Service (IHS). - FDA products and actions: - BROMFED-DM syrup (ANDA 088811), with brompheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride, is listed as discontinued; FDA determined it was not withdrawn for safety or effectiveness reasons. Additional qualifying ANDAs may be approved. - FDA proposes withdrawing approval of Salerno Pharmaceuticals’ Flolipid suspension (NDA 206679; 20 mg/5 mL and 40 mg/5 mL) because required annual reports were repeatedly not filed. The NDA holder may request a hearing, and interested parties may submit comments. - IHS: The Fiscal Year 2027 CHEF threshold is $20,258. - Procurement status: This is a regulatory and program-threshold notice, not a solicitation; no products or services are being purchased.
Description
The FDA proposes to withdraw approval of NDA 206679 for Flolipid suspension in 20 mg/5 mL and 40 mg/5 mL strengths. The proposal is based on Salerno Pharmaceuticals repeatedly failing to submit required annual reports and not responding to the agency’s request for those reports. The NDA holder may request a hearing by December 18, 2026, and must submit supporting data and analyses by January 19, 2027. Electronic or written comments are also due January 19, 2027.